A Phase II/III, prospective, multi-center, randomized, 4-week, double-blind, placebo-controlled study, designed to determine the safety, tolerability, EEG effects and efficacy of oral doses of 30 mg bid of evenamide (NW-3509) in patients with chronic schizophrenia who are symptomatic on their current second-generation antipsychotic (aripiprazole, clozapine, quetiapine, olanzapine, paliperidone, or risperidone) medication
Latest Information Update: 20 Sep 2024
At a glance
- Drugs Evenamide (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Newron Pharmaceuticals
- 19 Sep 2024 According to a Newron Pharmaceuticals media release,Newron will be presenting the results of study 008A at the upcoming 37th ECNP Congress (September 21-24, 2024) in Milan, Italy.
- 17 Jul 2024 This trial has been completed in Czech Republic, as per European Clinical Trials Database record.
- 25 Jun 2024 According to a Newron Pharmaceuticals media release, data form this trial were presented Investor Day 2024 in New York City.